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THE proper development ofchemotherapy in the management ofthe malignant
reticuloses requires that comparisons are made between va.rious compounds, and
with other methods oftreatment.
Before a compound reaches the point of clinical trial a great deal of thought
andworkhas been already expended. We are not here concerned with the starting
points of those trains of thought that lead to the synthesis of a substance.
Synthesis is followed by experimental work on animals and animal tumours and
in these tests a compound may show promise. At this point the clinician who is
forever seeking compounds of value will willingly but cautiously put it to clinical
test. He owes it to his patients to do so; he also owes it to the experimental
worker to give an objective opinion, on the basis of which further work may be
either extended or abandoned.
This paper is concerned with this final phase, that ofclinical trial and methods
of comparison as these have been applied to some common agents. It is intended
primarily for the experimental worker to demonstrate not only the limits of our
ability to discern the consequences of clinical trial but also to show some of the
problems in the clinical approach.
Any assessment of the efficiency of a new chemotherapeutic agent must be
based against standard treatments. These should include not only well tested
compounds but also irradiation methods where these are applicable.
It is important to emphasise that to-day the clinical aim is still palliation for
the vast majority of patients. Cure can only be hoped for in a small number of
the strictly localised lymphomas and in these it is a radiotherapy achievement.
So with palliation as the immediate objective we are concerned with assessing the
length and quality ofa remission, the freedom from toxic side effects, and not least
the general convenience ofthe patient.
At the start, therefore, there is the task of defining the term " remission ".
It would be academically sound to measure the remission as the number of weeks
after treatment until the patient is as a whole no better than he was at the begin-
ning. This is a workable concept in the assessment of remission in solid types of
reticuloendothelial disease. It is not a desirable definition for the chronic leuk-
aemias who are usually re-treated before such a state occurs. So for the chronic
leukaemias I propose to regard a remission as ending when the clinical evidence
shows clearly that the patient is deteriorating. The indices of this include a sig-
nificant fall in haemoglobin and rise in the primitive cells of the peripheral blood
even although neither symptom has deteriorated to pretreatment levels.
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It is possible to state at any stage in the observation of a treated patient that
a symptom is improving or is stationary or is progressing, relative to the same
symptom before treatment. Such a statement can be given a numerical figure.
The average of these figures for all the symptoms constitutes a " clinical index"
which sums up the condition of the patient and hence measures the quality of
remission. An index which falls to a certain limit can then be used to define the
end of a remission.
TABLE I.-Clinical Indices-Case ofMyeloid Leukaemia
4 months 12 months
Nodes
Neck
Axilla l
Groin r
Other J
Spleen . . . 2 . 2
Liver . . .
Bone marrow . . . 2 1
Haemoglobin . . 2 2
W.B.C. . . . 2 . 1
Primitive cells . . . 2 . 1
Weight . . . . 2 . 0
Well-being . . 2 . 1
Ability to work . . 2 . 1
169 Index -= 2-0 Index-9-1 1 8 8
Table I shows a number ofsymptoms so assessed in a case of chronic myeloid
leukaemia at 4 months and 12 months after treatment. Opposite each symptom
is anumber. The code is " 2 " for improvement, " 1 " for anunchanged symptom,
and " 0 " for an advancing symptom. A dash means either that a symptom was
not present or alternatively that the clinician forgot to annotate it. The average
ofthese figures at 4 months was 2-0. With this mean value the patientwasvastly
improved. At 12 months, however, the average was 1
- and the remission was
ending.
TABLE II.-Clinical Indices-Case ofHodgkin's Disease
2 months 4 months
Superficial nodes
Neck - Axillae 2 . . 1-5 . 1-0
Groins 1 J
Mediastinum . . . 0
Spleen . . 1 1
Liver. . . - -
Effusions
Haemoglobin . . 2-0 2-0
Fever . . . 2-0 . 0
Well-being . . 2-0 1.0
Weight . . . 2-0 . 1.0
Ability to work . . 2-0 . 10
Index = 2= 1*8 Index = O-88 7 5
Table II shows a similar study of a case of Hodgkin's disease. The mean
index at 2 months was 1-8; the patient was much improved. At 4 months, how-
ever, the figure was below 1-0 and the remission was over.EDITH PATERSON
The criteria on which the figures are chosen are important but they are too
detailed to describe here. Other criteria might well be used. The only measure
of validity is that the index arrived at should agree with a clinical impression of
the patient as a whole.
The method is not intended to indicate when treatment should be re-instituted
-this depends on many other factors. It is only a simple way of expressing the
total clinical impression for assessment purposes, in a way which will sort out a
welter of symptoms and so facilitate a tabulation of comparative figures on an
objective basis. It will not only give us a figure for the length of a remission, it
will also estimate the amount ofbenefit received, and, on a closer analysis, it can
be used to look at individual symptoms which might be specifically benefited by
a particular agent.
The use of the method is best illustrated by examples in which comparisons
have been made between different treatments. The first concerns the approach
to measuring response in chronic myeloid leukaemia.
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Chronic Myeloid Leukaemia
Fig. 1-5 each summarise the career of a case of chronic myeloid leukaemia
treated by various agents. The sequence ofevents will be familiar to all clinicians
but perhaps less so to those working in the experimental field. These histories
are being used to illustrate what I think to be a general truth, that only the first
treatment of a leukaemic patient should be used in the comparative assessment
of compounds.
The height of the column denotes the period during which the patient was in
remission. Ifno remission occurred during a treatment, that is to say, ifthe index
was 1-0 or less, the column has been barred diagonally.
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The patient illustrated in Fig. 1 was given 32P as the first treatment with in
consequence a remission ofover 2 years. At the end ofthis remission he was given
the chemical compound B.E.P. (1: 3-bis (ethyleneiminosulphonylpropane)), and
a further good remission of 11 months followed. This ended when the patient
stopped taking B.E.P. on account ofnausea. Myleran was, therefore, substituted.
The response was slower and the remission was shorter. The last three courses
with mercaptopurine, myleran and a last treatment with 32P were all ineffective.
This case illustrates that the duration of remissions steadily diminished and that
the same 32P which apparently was most suitable at an early stage, was entirely
unhelpful terminally.
This next case (Fig. 2), was given splenic irradiation as the first method of
treatment. This patient had a prolonged remission for over three and a halfyears.
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The treatment was changed to myleran because the spleen seemed to be becoming
resistant. This remission lasted for about one year. The patient then deteriorated
rapidly.
On the basis of these cases it might seem that myleran was rather ineffectual
compared with irradiation methods. Fig. 3 however shows myleran in a very
different light. This patient was treated by myleran as the first and only treat-
ment. She waskept in goodhealth forthree and ahalfyears and died afewmonths
after the remission ended. It is interesting to note here that at the beginning the
amount of myleran required to give freedom from symptoms was small; later,
sustained maintenance dosage was required.
Fig. 4 illustrates the use of urethane in inducing a remission which lasted for
335
n If 36 r-
30
1-
6
v- imm L %FEDITH PATERSON
over three years. Splenic irradiation resulted in a much shorter remission. Finally
mercaptopurine yielded only a transient response.
The lastpatient, (Fig. 5), was treatedby monthly doses oftriethylene melamine
(T.E.M.) and did well for 16 months. At the end of the remission B.E.P. was
given unsuccessfully. X-ray therapy to the spleen was effective for a very short
time; no benefit was obtained with myleran.
These are examples; similar pictures could be shown of other chemothera-
peutic agents. These diagrams all illustrate the principle of diminishing returns.
They serve to show how important it is to test compounds in patients at a stage
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when they are capable of responding and it would seem important to evaluate a
new compound on its use as the first agent in treatment.
If this is accepted it follows that very few centres to-day can get an answer
about a new treatment quickly, based on the first treatment of their own clinical
material. Ofrecent yearsthedifficultyhasfurtherincreasedbecause manypatients
have already been treated by individual physicians before reaching a centre
engaged in clinical investigation.
The conclusion is obvious that important comparisons should be done on a
national or international basis. This would imply rules for random selection of
patients and carefully thought out standards of measurement. For future assess-
ments ofchemotherapeutic compoundsin chronic myeloidleukaemiaitis suggested
that splenic irradiation might well be the best control treatment; this does not
mean resurrecting the dusty histories of 20 years ago to compare with a new
compound, but rather the selection of contemporary cases for treatment, on a
random basis.
Another point is illustrated by these five patients. All had clinical indices of
the order of 2 during their first remission; and in all of them the first treatment
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yielded a fairly long remission. Yetthis rather uniform result was obtained with
verydiverse agents. Onewonders whether all these agents are " specific " or that
none is.
Generalised Hodgkin's Disease
In the solid reticuloses the use of a compound as the first treatment may be
rather less decisive in its effects, than in the leukaemias. Generalised Hodgkin's
disease has been used to exemplify the comparison of 2 compounds on the basis of
clinical indices. The clinical material comprises 80 section-proved cases, chosen on
the soleground ofhavingeachbeentreatedbyatleast 2different chemotherapeutic
agents, including nitrogen mustard and triethylene melamine which will be
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compared. Individual cases in this group were also treated with other chemical
compounds or irradiation. Such other treatments have been exluded from the
present analysis.
These generalised cases have been grouped, depending on the order in which
the compounds were given. I am comparing, therefore, nitrogen mustard and
T.E.M. where these agents were the first treatments, and the same compounds
when these were given as later treatments.
The comparisons are shown in Tables III toVII; these summarise the relative
effects ofnitrogen mustard and T.E.M. in terms of:
(a) The fraction ofresponding patients.
(b) The length ofthe response.
(c) The quality ofthe response.
(d) Undesirable side effects.
(a) Thefraction ofcases responding
This has been taken as the number ofpatients whose index was over 1F0 eight
weeks or more after treatment. It excludes transitory betterment of shorter
duration.
It will be observed that either agent given as a first treatment induced a higher
remission ratethanifgiven subsequently. The difference betweenthe lst andlater
25
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TABLE III.-Compari8on between HN2 and T.E.M. in Hodgkin'8 Disease
Fraction of patients benefited 8 weeks after treatment
Benefited
(%)
HN2-lst treatment . . . 80
T.E.M.-lst treatment . . . 70
HN--later treatment . . . 48
T.E.M.-later treatment . . . 57
treatment with HN2, i.e., between 80 and 48 per cent is significant at the 5 per
cent level, and is in line with the leukaemia findings. Nitrogen mustard appears
somewhat more successful than T.E.M. as a first treatment, and T.E.M. seems
more impressive as a later treatment.
(b) The length ofthe re8ponse
This compares the length of remission of the same group of patients who
showed betterment at 8 weeks.
TABLE IV.-Comparison Between HN2 and T.E.M. in Hodgkin's Di8ease
Length of remission in weeks
Median
(weeks)
HN2-lst treatment . . . 22
T.E.M.-Ist treatment . . . 12
HN,-later treatment . . . 8
T.E.M.-later treatment . . . 12
Thelength of remission from HN2 as a first treatment was longer than when
T.E.M. was employed. However, for subsequent treatments T.E.M. again seemed
to be preferable to HN2.
While both tables appear to favour HN2 as a first treatment, and T.E.M. as a
later treatment, the differences are not significant with the numbers available. It
is therefore unnecessary to speculate on the interpretation.
(c) The quality ofthe response
This is a comparison of the clinical index of those responding cases, 8 weeks
after treatment:
TABLE V.-Comparison between HN2 and T.E.M. in Hodgkin's Disease
Clinical index at 8 weeks
Mean index-
Responding patients
HN2-lst treatment . . . 1'6
T.E.M.-lst treatment . . 1-5
HN2-later treatment . . 1-6
T.E.M.-later treatment . 1-5
It would seem that for both first and later treatments nitrogen mustard
appeared to be a fraction superior to T.E.M. but the difference ifpresent was very
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small. The figures also suggest that the quality of a remission was about the same
for first and for later treatments with either compound.
(d) Side effects
An important consideration in the comparison oftwo compounds relates to the
undesirable side effects. Nitrogen mustard has the well known disadvantage of
inducing transient gastrointestinal symptoms and sometimes venous thrombosis;
T.E.M. is given orally in enteric coated tablets and if given in instalments is free
ofthese side effects. This point is conceded and needs no elaboration.
The depression of the haemopoietic system can perhaps be briefly contrasted
by examining the effects on two elements of the circulating blood-the haemo-
globin and the platelets. The comparative effects ofthe two compounds on haemo-
globin is shown in Table VI which is based on all patients whether they benefited
or not provided that the data on their blood counts was available, and irrespective
ofthe order in which compounds were given. Depression ofhaemoglobin has been
taken as a fall of 10 per cent or more following treatment.
TABLE VI.-Comparison Between HN2 and T.E.M. in Hodgkin's Disease
Reduction in haemoglobulin-all cases
Cases
(%) HN2 . . . 18
T.E.M. . . 23
Eighteen per cent of the HN2 patients showed this against 23 per cent of the
T.E.M. patients. If this difference were significant it would be important to the
clinician. It is, however, not significant, and for both compounds the recovery
time of the haemoglobin was the same. There was no difference in the haemo-
globin depression between first and later treatments with either compound.
TABLE VII.-Comparison Between HN2 and T.E.M. in Hodgkin's Disease
Reduction in platelets
Cases
(%)
HN2 . . . 33
T.E.M. . . 35
The standard measurement of platelet depression was a reduction of 25 per
cent or more in the platelet count. The figures of 33 per cent for HN2 and 35 per
cent for T.E.M. are very close, and the recovery times were similar for the two
compounds. There was no difference between first and later treatments with
either compound.
Studies of the other cells of the circulating blood have not shown differences
between HN2 and T.E.M.
For the future evaluation ofnew compounds for generalised Hodgkin's disease
a control method of treatment is required. Nitrogen mustard itself would be
suitable, onthegrounds ofthevast clinicalexperience whichhasbeenaccumulated.
These clinical comparisons do not have the elegance oflaboratory experiment.
Forexample nitrogenmustard andT.E.M. havebeen comparedonanimaltumours,
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notably by Druckrey et al. (1956) and by Oettel and Wilhelm (1957). Nevertheless
it is of interest that for the Yoshida ascites-tumour in rats, these authors have
shown comparisons which resemble the clinical findings in Hodgkin's disease.
The differences between the two compounds for other animal tumours should
stimulate interest in seeking differences in effect which may exist for other human
tumours.
Localised Hodgkin's Disease
Finallyhere is afurtherbriefillustration ofmeasurement. Thereis ajustifiable
hypothesis that two agents in combination might be more effective. This may be
based on the idea of synergism as exemplified by the combination of mercapto-
purine with azaserine in acute leukaemia. Or it may be based on the idea that a
systemic agent might control small undetected foci of disease while a local agent
such as X-rays eradicated a mass.
Some time ago we tested this second idea in early cases of Hodgkin's disease
still apparently localised to one region-neck or axilla. We compared cases
treated with regional x-irradiation aJone with cases treated by regional x-irradia-
tionplusafulldoseofnitrogenmustardgivenaspartofthefirstplannedtreatment.
Ifthe hypothesis was sound this would be shown as a lengthening ofthe survival
time ofthe patient or at least as a lengthening of the first remission. The results
are shown in Tables VIII and IX.
TABLE VIII.-Comparison Between HN2 + X-rays with X-rays Given Alone
Localised Hodgkin's disease
The 5-year survival
Number treated Crude % survival
Treated by HN2 + X-ray . 35 . 54
Treated by X-ray alone . 32 . 59
TABLE IX.-CoMparison Between fN2 + X-rays with X-rays Given Alone
Localised Hodgkin's disease
Length of 1st remission (assessed at 5th year)
Median
(months)
HN2 +X-ray . . . 46
X-ray alone . . . 50
The differences shown in Tables VIII and IX are not significant and they do
not support the hypothesis that the combined treatment carried any advantage.
A similar examination based on other types ofmalignant diseaseorwithother
compounds might not lead to the same conclusion. This study applies only to
Hodgkin's disease and it is included to show that the method of measurement
must vary with the information one is looking for.
SUMMARY
(1) The present-day needs for the advancement of chemotherapy include
critical comparisons using defined clinical indices.
(2) The most valuable comparisons are between the effects of different agents
as the first treatment and using the average length of remission as the standard.
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This requires collaborative work between centres in order to get information that
is speedy and significant.
(3) Other effects such as the remission rate or the quality of a remission can
equally be assessed by the use of a clinical index, and for certain purposes the
survival time may be useful.
(4) For each disease studied a well tested method of treatment is required as
a control for a new compound. This implies that treatments should be carried out
on a random basis.
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